搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
4 小时
on MSN
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
1 小时
Ozempic or Mounjaro weight loss jabs to be given to obese unemployed people to help them ...
Health Secretary Wes Streeting has suggested that new weight loss injections such as Ozempic or Mounjaro could be given to ...
7 小时
on MSN
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
FiercePharma
15 小时
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
11 天
减肥神药回归:礼来药物短缺结束,平替厂商未来何去何从?
在全球对肥胖症治疗愈加重视的背景下,礼来的减肥神药被广泛关注。但就在最近,FDA(美国食品和药物管理局)宣布,礼来公司两款主要的GLP-1类注射剂——Zepbound和Mounjaro的供应短缺问题已经得到解决,这让很多关注减肥药物的人倍感兴奋。但对仿制药厂商Hims&Hers来说,却是一场重大的打击,其股价盘中一度大跌15%。那么,调控政策的变化究竟意味着什么?
12 天
美国食品药品监督管理局:礼来公司的减肥药不再短缺
美国食品和药物管理局说,以治疗糖尿病的Mounjaro和控制体重的Zepbound名义销售的所有剂量的药物——替扎帕肽——的短缺问题已经解决。 对 Mounjaro 和 Zepbound 的需求激增促使礼来公司投资数十亿美元提高这两种药物的产量。丹麦制药商 诺和诺德 公司(Novo Nordisk NOVOb.CO)也在努力增加供应,以满足前所未有的需求。
Becker's Hospital Review
14 小时
FDA to reconsider decision barring sale of compounded Mounjaro: 5 things to know
The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.
21 小时
Tori Spelling’s Weight Loss of 40 lbs Using Mounjaro And Ozempic
Here are insights into Tori Spelling’s weight loss journey and how the actress toned herself down. From medications to diet ...
11 天
on MSN
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
The Hill
11 天
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
3 天
on MSN
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...
11 天
德意志银行维持礼来股票买入评级
在分析师评级方面,BMO Capital维持礼来的"优于大市"评级,对公司新任首席财务官Lucas Montarce表示信心。德意志银行和Cantor Fitzgerald也分别维持了公司的买入和增持评级。
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈